AnaptysBio reports Q2 FY26 results; Jemperli and Quimilza milestones flagged
AnaptysBio reported Q2 FY26 results. It said Jemperli is showing year-over-year growth, with potential FDA actions and a litigation judgment expected within 6 months. The company also said it expects an FDA decision for Quimilza in December 2026.